Exchange Traded Concepts Trust

ROBO Global® Healthcare Technology and Innovation ETF

Ticker: HTEC
Principal Listing Exchange: NYSE Arca
Annual Shareholder Report: April 30, 2026

This annual shareholder report contains important information about the ROBO Global® Healthcare Technology and Innovation ETF (the "Fund") for the period from May 1, 2025 to April 30, 2026. You can find additional information about the Fund at https://roboglobaletfs.com/investor-materials. You can also request this information by contacting us at 855-456-ROBO (7626).

What were the Fund costs for the last year?

(based on a hypothetical $10,000 investment)

Fund Name	Costs of a $10,000 investment	Costs paid as a percentage of a $10,000 investment
ROBO Global® Healthcare Technology and Innovation ETF	$76	0.68%

How did the Fund perform in the last year?

The Fund seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the ROBO Global® Healthcare Technology and Innovation Index. The Fund had positive performance during the fiscal year ending on April 30, 2026. The Fund returned 24.45% while the VettaFi Full World Index, the Fund's primary broad-based index, gained 31.56%. The Fund's secondary benchmark, the S&P 500® Index, gained 31.05%.

Seven of the nine subsectors that the Fund invests in posted gains this past year, with the key driver of performance being Regenerative Medicine, which returned 123.97%. The positive numbers were largely driven by key regulatory approvals, breakthrough clinical trial data, and strong commercial sales growth from holdings like AxoGen (+165.52%), United Therapeutics (+88.51%), and Artivion (+51.25%), complemented by strong showings from companies such as Arrowhead Pharmaceuticals (+429.01%) and Exact Sciences (+129.86%) in other subsectors.

Challenges during the reporting period included impacts on subsectors like Data Analytics and Medical Instruments due to hospital capital expenditures tightening and elongated enterprise software sales cycles. These subsectors were further dragged down by specific operational hurdles such as supply chain constraints, product recalls, and delayed biopharma R&D spending, reflected in the notable declines of holdings such as Boston Scientific (-44.00%), Integra LifeSciences (-35.69%), and Veeva Systems (-33.26%).

How did the Fund perform since inception?

Total Return Based on $10,000 Investment



Average Annual Total Returns as of April 30, 2026

Fund/Index Name	1 Year	5 Years	Annualized Since Inception
ROBO Global® Healthcare Technology and Innovation ETF	24.45%	-6.20%	4.88%
VettaFi Full World Index (USD) (TR)*	31.56%	11.12%	13.54%
S&P 500 Index (USD) (TR)*	31.05%	13.14%	15.72%
ROBO Global® Healthcare Technology and Innovation Index (USD) (NR)†	25.31%	-5.59%	5.59%

Since its inception on June 24, 2019. The line graph represents historical performance of a hypothetical investment of $10,000 in the Fund since inception. Returns shown are total returns, which assume the reinvestment of dividends and capital gains. The table and graph presented do not reflect the deduction of taxes a shareholder would pay on Fund distributions or the redemption of Fund shares. ***Past performance is not indicative of future performance.*** *Call 855-456-ROBO (7626) or visit https://roboglobaletfs.com/investor-materials for current month-end performance.*

* Total Return (TR) - Reflects no deductions for fees, expenses or taxes.

† Net Return (NR) - Reflects no deductions for fees, expenses or taxes (except foreign withholding taxes).

Key Fund Statistics as of April 30, 2026

Total Net Assets	Number of Holdings	Total Advisory Fees Paid	Portfolio Turnover Rate
$53,336,595	60	$333,622	38%

What did the Fund invest in?

Sector Weightings*



* Percentages are calculated based on total net assets.

Top Ten Holdings

Holding Name	Percentage of Total Net Assets(A)
Axogen	3.2%
Arrowhead Pharmaceuticals	2.6%
Twist Bioscience	2.3%
Glaukos	2.2%
Natera	2.2%
Tempus AI, Cl A	2.1%
Novocure	2.0%
Alnylam Pharmaceuticals	2.0%
Guardant Health	2.0%
Thermo Fisher Scientific	2.0%

(A) Short-Term Investments are not shown in the top ten chart.

Material Fund Changes

There were no material changes during the reporting period.

Changes in and Disagreements with Accountants

There were no changes in or disagreements with accountants during the reporting period.

Additional Information

For additional information about the Fund, including its prospectus, financial information, holdings, and proxy voting information, call or visit:

- 855-456-ROBO (7626)
- https://roboglobaletfs.com/investor-materials

Householding

Rule 30e-1 of the Investment Company Act of 1940, as amended, permits funds to transmit only one copy of a proxy statement, annual report or semi-annual report to shareholders (who need not be related) with the same residential, commercial or electronic address, provided that the shareholders have consented in writing and the reports are addressed either to each shareholder individually or to the shareholders as a group. This process is known as "householding" and is designed to reduce the duplicate copies of materials that shareholders receive and to lower printing and mailing costs for funds. Once implemented, if you would like to discontinue householding for your accounts, please call toll-free at 855-456-ROBO (7626) to request individual copies of these documents. Once the Fund receives notice to stop householding, we will begin sending individual copies 30 days after receiving your request.